| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8268e39ce70ff2ad19742e2a21d5a90c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2037-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M37-0092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-325
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015 |
| filingDate |
2014-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4426f137fbad815c0a063bef330fba7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2c00b2d69d4d1f160df09d8c9e5dfea |
| publicationDate |
2016-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016000707-A1 |
| titleOfInvention |
Methods of inhibiting cataracts and presbyopia |
| abstract |
Described herein are methods of inhibiting or reversing the progression of cataract formation or presbyopia in an eye by administering a γ-crystallin charge masking agent. Both presbyopia and cataracts are caused by aggregation of the soluble crystalline lens proteins called the crystallins. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10736863-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10413529-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023310471-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9675589-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023310380-A1 |
| priorityDate |
2013-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |